Many T-ALL cells express CD38 on their surface, and treatment of T-ALL cells with ATRA increases CD38 expression, which further enhances antibody-dependent cellular phagocytosis (ADCP) in macrophages and ADCC, especially when using daratumumab-IgA2 (Baumann et al., 2022). Here, CD38 is linked to acute lymphoblastic leukemia.